Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J0692
500 MG
Medicare payment limit per unit (Q4 2026): $1.292
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 12 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| Facility outpatient hospital services | 12 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| DME supplier services | 12 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$1.292per 500 MG
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $1.292 | 500 MG | 20% | −0.3% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $1.296 | 500 MG | 20% | +2.2% |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 60505-6144-04 | CefepimeApotex Corp | 1 × 10 | 2 | 20 | $25.84 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 60505-6145-04 | CefepimeApotex Corp | 1 × 10 | 4 | 40 | $51.68 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 60505-6146-00 | CefepimeApotex Corp | 1 × 1 | 2 | 2 | $2.58 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 60505-6146-04 | CefepimeApotex Corp | 1 × 10 | 2 | 20 | $25.84 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 60505-6147-00 | CefepimeApotex Corp | 1 × 1 | 4 | 4 | $5.17 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 60505-6147-04 | CefepimeApotex Corp | 1 × 10 | 4 | 40 | $51.68 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 60505-6245-04 | CefepimeApotex Corp | 1 × 10 | 2 | 20 | $25.84 | ASP | Q4 2023 – Q4 2026 | ListedCefepime |
| 60505-6246-04 | CefepimeApotex Corp | 1 × 10 | 4 | 40 | $51.68 | ASP | Q4 2023 – Q4 2026 | ListedCefepime |
| 63323-0326-20 | MaxipimeFreseniUS Kabi USA, LLC | 1 × 10 | 2 | 20 | $25.84 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 63323-0340-20 | MaxipimeFreseniUS Kabi USA, LLC | 1 × 10 | 4 | 40 | $51.68 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 00143-9382-10 | CefepimeHikma Pharmaceuticals USA Inc. | 1 × 10 | 2 | 20 | $25.84 | ASP | Q2 2026 – Q4 2026 | ListedCefepime Hydrochloride |
| 00143-9383-10 | CefepimeHikma Pharmaceuticals USA Inc. | 1 × 10 | 4 | 40 | $51.68 | ASP | Q2 2026 – Q4 2026 | ListedCefepime Hydrochloride |
| 00409-9566-10 | CefepimePfizer Inc | 1 × 10 | 2 | 20 | $25.84 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 00409-9735-10 | CefepimePfizer Inc | 1 × 10 | 4 | 40 | $51.68 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 66794-0209-41 | CefepimePiramal Critical Care Inc | 1 × 10 | 2 | 20 | $25.84 | ASP | Q1 2021 – Q4 2026 | Excluded listingCefepime |
| 25021-0121-20 | CefepimeSagent Pharmaceuticals | 1 × 10 | 2 | 20 | $25.84 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 25021-0121-66 | CefepimeSagent Pharmaceuticals | 1 × 10 | 2 | 20 | $25.84 | ASP | Q1 2021 – Q4 2026 | Excluded listingCefepime |
| 25021-0122-50 | CefepimeSagent Pharmaceuticals | 1 × 10 | 4 | 40 | $51.68 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 25021-0122-67 | CefepimeSagent Pharmaceuticals | 1 × 10 | 4 | 40 | $51.68 | ASP | Q1 2021 – Q4 2026 | Excluded listingCefepime |
| 44567-0130-10 | CefepimeWG Critical Care, LLC | 1 × 10 | 2 | 20 | $25.84 | ASP | Q4 2022 – Q4 2026 | ListedCefepime |
| 44567-0131-10 | CefepimeWG Critical Care, LLC | 1 × 10 | 4 | 40 | $51.68 | ASP | Q4 2022 – Q4 2026 | ListedCefepime |
| 44567-0240-10 | CefepimeWG Critical Care, LLC | 1 × 10 | 2 | 20 | $25.84 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
| 44567-0241-10 | CefepimeWG Critical Care, LLC | 1 × 10 | 4 | 40 | $51.68 | ASP | Q1 2021 – Q4 2026 | ListedCefepime |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 00264-3193-11 | Cefepime HCL in DextroseB. BRAUN MEDICAL INC. | 1 × 24 | 2 | 48 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2002 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| Prescribing Information |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $1.268 | 500 MG | 20% | +46.4% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.866 | 500 MG | 20% | −29.1% | AMP-based payment limit |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $1.222 | 500 MG | 20% | −0.7% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $1.230 | 500 MG | 20% | +2.4% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $1.201 | 500 MG | 20% | −3.0% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $1.238 | 500 MG | 20% | +1.7% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $1.217 | 500 MG | 20% | −4.5% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $1.275 | 500 MG | 20% | −4.6% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $1.337 | 500 MG | 20% | +5.9% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $1.262 | 500 MG | 20% | −0.6% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $1.270 | 500 MG | 20% | +3.6% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $1.226 | 500 MG | 20% | −1.0% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $1.238 | 500 MG | 20% | −3.8% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $1.287 | 500 MG | — | −26.0% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $1.740 | 500 MG | — | −2.0% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $1.776 | 500 MG | — | −0.2% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $1.779 | 500 MG | — | +1.2% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $1.758 | 500 MG | — | −5.0% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $1.850 | 500 MG | — | −2.1% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $1.889 | 500 MG | — | −0.9% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $1.906 | 500 MG | — | +5.2% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $1.812 | 500 MG | — | — | — |
|---|
| 00264-3195-11 | Cefepime HCL in DextroseB. BRAUN MEDICAL INC. | 1 × 24 | 4 | 96 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedCefepime Hydrochloride And Dextrose |
|---|
| 00338-1301-41 | Cefepime HCLBAXTER | 50 × 24 | 2 | 48 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedCefepime |
|---|
| 00338-1301-48 | Cefepime HCLBAXTER | 100 × 12 | 4 | 48 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedCefepime |
|---|
| 00409-0217-01 | MaxipimePFIZER INC. | 1 × 25 | 2 | 50 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingMaxipime |
|---|
| 00409-0218-01 | MaxipimePFIZER INC. | 1 × 25 | 4 | 100 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingMaxipime |
|---|
| 00409-0219-01 | MaxipimePFIZER INC. | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingMaxipime |
|---|
| 00409-0220-01 | MaxipimePFIZER INC. | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingMaxipime |
|---|
| 66794-0210-41 | CefepimePiramal Critical Care Inc | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingCefepime |
|---|
| 70594-0089-02 | CefepimeXellia Pharmaceuticals USA, LLC. | 1 × 10 | 2 | 20 | ASP | Q2 2022 – Q2 2026Not in Q4 2026 file | Excluded listingCefepime Hydrochloride |
|---|
| 70594-0090-02 | CefepimeXellia Pharmaceuticals USA, LLC. | 1 × 10 | 4 | 40 | ASP | Q2 2022 – Q2 2026Not in Q4 2026 file | Excluded listingCefepime Hydrochloride |
|---|